İrritabl Bağırsak Sendromu
Synopsis
Irritable Bowel Syndrome (IBS) is the most common functional gastrointestinal disorder, characterized by abdominal pain, bloating, and altered bowel habits in the absence of structural or biochemical abnormalities. Its multifactorial etiology involves altered gastrointestinal motility, visceral hypersensitivity, brain-gut axis interactions, microbiota changes, and stress. Worldwide prevalence ranges from 10% to 15%, with a higher predominance in females and individuals aged 20–50 years. Diagnosis relies primarily on a detailed medical history, physical examination, and the Rome IV criteria, avoiding unnecessary invasive tests unless alarm symptoms are present. Based on the Bristol Stool Form Scale, IBS is classified into four subtypes: diarrhea-predominant (IBS-D), constipation-predominant (IBS-C), mixed (IBS-M), and unclassified (IBS-U). Management focuses on establishing a strong patient-physician relationship and targeted symptom relief. First-line management includes laxatives, antidiarrheals, antispasmodics, lifestyle modifications, and a low-FODMAP diet, whereas second-line strategies for non-responsive cases involve central neuromodulators such as antidepressants (TCAs, SSRIs), 5-HT4 agonists, 5-HT3 antagonists, rifaximin, and psychological therapies like cognitive behavioral therapy or hypnotherapy.
References
Drossman DA, Corrazziari E, Delvaux M, Spiller R, Talley NJ, Thompson WG. Rome III: The Functional Gastrointestinal Disorders. McLean, VA: Degnon Associates; 2006.
Occhipinti K, Smith JW. Irritable bowel syndrome: a review and update. Clin Colon Rectal Surg. 2012;25:46–52.
Dekel R, Drossman DA, Sperber AD. The use of psychotropic drugs in irritable bowel syndrome. Expert Opinion on Investigational Drugs. 2013;22:329–339.
Mayer EA, Tillisch K. The brain-gut axis in abdominal pain syndromes. Annual Review of Medicine. 2011;62:381–396.
Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002;123:2108–2131.
Whitehead WE, Burnett CK, Cook EW, Taub E. Impact of irritable bowel syndrome on quality of life. Dig Dis Sci. 1996;41:2248–2253.
Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson WG, Whitehead WE, Janssens J, Funch-Jensen P, Corazziari E. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci. 1993;38:1569–1580.
Saha L. Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence-based medicine.World J Gastroenterol. 2014 Jun 14; 20(22): 6759–6773.
Grundmann O, Yoon SL. Complementary and alternative medicines in irritable bowel syndrome: An integrative view. World Journal of Gastroenterology. 2014;20:346–362.
Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clinical Epidemiology. 2014;6:71–80.
Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015 Mar 03;313(9):949-58.
Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012 Jul;10(7):712-721.
Sperber AD, Dumitrascu D, Fukudo S, Gerson C, Ghoshal UC, Gwee KA,Whitehead W. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: A Rome Foundation working team literature review. Gut. 2016;0:1–8.
Inadomi JM, Fennerty MB, Bjorkman D. Systematic review: The economic impact of irritable bowel syndrome. Alimentary Pharmacology & Therapeutics. 2003;18:671–682.
Kılıç SP, Ovayolu N, Koruk M. (2017) İrritabl Barsak Sendromlu Hastalarda Yaşam Kalitesi. İzmir KâTip Çelebi Üniversitesi Sağlık Bilimleri Fakültesi Dergisi, 2(2): 27-32.
Lee YJ, Park KS. Irritable bowel syndrome: Emerging paradigm in pathophysiology. World Journal of Gastroenterology. 2014;20:2456–2469.
Fukudo S, Kanazawa M. Gene, environment, and brain-gut interactions in irritable bowel syndrome. Journal of Gastroenterology and Hepatology. 2011;26:110–115.
Card T, Enck P, Barbara G, et al. Post-infectious IBS: Defining its clinical features and prognosis using an internet-based survey. United European Gastroenterol J 2018; 6:1245-53.
Heitkemper M, Jarrett M, Jun SE. Update on irritable bowel syndrome program of research. Journal of Korean Academy of Nursing. 2013;43:579–586.
Fichna J, Storr MA.Brain-gut interactions in IBS. Frontiers in Pharmacology. 2012;3:1–12.
Riddle MS, Welsh M, Porter CK, Nieh C, Boyko EJ, Gackstetter G, Hooper TI. The epidemiology of irritable bowel syndrome in the US military: Findings from the millennium cohort study. American Journal of Gastroenterology. 2016;111:93–104.
Ohman L, Simren M. New insights into the pathogenesis and pathophysiology of irritable bowel syndrome. Digestive and Liver Disease. 2007;39:201–215.
Camilleri M. Physiological underpinnings of irritable bowel syndrome: Neurohormonal mechanisms. Journal of Physiology. 2014;592:2967–2980.
Stasi C, Rosselli M, Bellini M, Laffi G, Mileni S. Altered neuro-endocrine-immune pathways in the irritable bowel syndrome: The top-down and the bottom-up model. Journal of Gastroenterology. 2012;47:1177–1185.
Weaver KR,Melkus GD,Henderson WA. Irritable Bowel Syndrome: A review.Am J Nurs. 2017 Jun; 117(6): 48–55.
Houghton LA, Lea R, Agrawal A, Reilly B, Whorwell PJ. Relationship of abdominal bloating to distention in irritable bowel syndrome and effect of bowel habit. Gastroenterology 2006; 131: 1003-10.
Whitehead WE, et al. Comorbidity in irritable bowel syndrome. Am. J. Gastroenterol. 2007; 102:2767–2776.
Manning, A. P., Thompson, W. G., Heaton, K. W., & Morris, A. F. (1978). Towards positive diagnosis of the irritable bowel. Br Med J, 2(6138), 653-654.
Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead WE. Rome II: The Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology, and Treatment: A Multinational Consensus. 2nd ed. McLean, VA: Degnon Associates; 2000.
Spiegel BM, Gralnek IM, Bolus R, et al. Is a negative colonoscopy associated with reassurance or improved health-related quality of life in irritable bowel syndrome? Gastrointest Endosc 2005; 62: 892-9.
Irvine AJ, Chey WD, Ford AC. Screening for celiac disease in irritable bowel syndrome: An updated systematic review and meta-analysis. Am J Gastroenterol 2017; 112:65-76.
The new faecal calprotectin care pathway. https://www.nice.org.uk/sharedlearning/the-new-fae-cal-calprotectin-care-pathway 2018. Accessed 14th December 2019
Menees SB, Powell C, Kurlander J, Goel A, Chey WD. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol 2015; 110: 758 444-54.
Drossman DA. 2012 David Sun lecture: helping your patient by helping yourself--how to improve the patient-physician relationship by optimizing communication skills. Am J Gastroenterol. 2013 Apr;108(4):521-8.
Johannesson E, Simren M, Strid H, Bajor A, Sadik R. Physical activity improves symptoms in irritable bowel syndrome: A randomized controlled trial. Am J Gastroenterol 2011; 106: 915-22.
Eswaran S. Tack J.,Chey W.D. Food:The forgotten factor in the irritable bowel syndrome. Gastroenterol. Clin. N. Am. 2011;40:141–162.
Dalrymple J., Bullock I. Diagnosis and management of irritable bowel syndrome in adults in primary care: Summary of NICE guidance. BMJ. 2008;336:556–568.
Tuck C.J., Muir J.G., Barrett J.S., Gibson P.R. Fermentable oligosaccharides, disaccharides, monosaccharides and polyols: Role in irritable bowel syndrome. Expert Rev. Gastroenterol. Hepatol. 2014;8:819–834.
Gibson P.R., Varney J., Malakar S., Muir J.G. Food components and irritable bowel syndrome. Gastroenterology. 2015;148:1158–1574.
Barrett J.S., Gearry R.B., Muir J.G., Irving P.M., Rose R., Rosella O., Haines M.L., Shepherd S.J., Gibson P.R. Dietary poorly absorbed, short-chain carbohydrates increase delivery of water and fermentable substrates to the proximal colon. Aliment. Pharmacol. Ther. 2010;31:874–882.
Ong D.K., Mitchell S.B., Barrett J.S., Shepherd S.J., Irving P.M., Biesiekierski J.R., Smith S., Gibson P.R., Muir J.G. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J. Gastroenterol. Hepatol. 2010;25:1366–1373.
Halmos E.P., Power V.A., Shepherd S.J., Gibson P.R., Muir J.G. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146:67–75.
Shepherd S.J., Lomer M.C., Gibson P.R. Short-chain carbohydrates and functional gastrointestinal disorders. Am. J. Gastroenterol. 2013;108:707–717.
Ford AC, Harris LA, Lacy BE, Quigley EMM, Moayyedi P. Systematic review with meta-analysis: The efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther 2018; 48: 1044-60.
Mansueto, P., Seidita, A., D’Alcamo, A., and Carroccio, A. (2015). Role of FODMAPs in Patients with Irritable Bowel Syndrome. Nutrition in Clinical Practice, 30(5), 665-682.
Chapman RW, Stanghellini V, Geraint M, Halphen M. Randomized clinical trial:Macrogol/PEG 3350 plus electrolytes for treatment of patients with consTip ation associated with irritable bowel syndrome. Am J Gastroenterol 2013; 108: 1508-15.
Ford AC, Moayyedi P, Chey WD, et al. American College of Gastroenterology monograph on management of irritable bowel syndrome. Am J Gastroenterol 2018; 113 (Suppl 2): 1-18.
Zheng L, Lai Y, Lu W, et al. Pinaverium reduces symptoms of irritable bowel syndrome in a multi-center, randomized controlled trial. Clin Gastroenterol Hepatol 2015; 13: 1285-92.
Gorard DA, Libby GW, Farthing MJ. Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome. Dig Dis Sci 1995; 40: 86-95.
Ford AC, Suares NC. Effect of laxatives and pharmacological therapies in chronic idipathic consTipation: Systematic review and meta-analysis. Gut 2011; 60: 209-18.
Ford AC, Lacy BE, Harris LA, Quigley EM, Moayyedi P. Effect of antidepressants and psychological therapies in irritable bowel syndrome: An updated systematic review and meta-analysis. Am J Gastroenterol 2019; 114: 21-39
Ford AC, Sperber AD, Corsetti M, Camilleri M. Irritable bowel syndrome. Lancet 2020 Nov 21;396(10263):1675-88.